Review
doi: 10.1002/1097-0142(197707)40:1<334::aid-cncr2820400147>3.0.co;2-x.
VM 26 and VP 16-213: a comparative analysis
- PMID: 328129
- DOI: 10.1002/1097-0142(197707)40:1<334::aid-cncr2820400147>3.0.co;2-x
Item in Clipboard
Review
VM 26 and VP 16-213: a comparative analysis
Cancer.
1977 Jul.
Abstract
VM 26 and VP 16-213 are epipodophyllotoxin analogs. This paper presents a comparative analysis of their experimental and clinical features but fails to disclose any significant difference between these drugs. Similar studies with other classes of compounds might help to define some rationale for the development of analogous cytotoxic agents.
Similar articles
-
Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.Cancer Treat Rep. 1979 Aug;63(8):1231-9. Cancer Treat Rep. 1979. PMID: 225026 Clinical Trial. No abstract available.
-
Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C.Cancer Treat Rev. 1979 Sep;6(3):153-64. doi: 10.1016/s0305-7372(79)80067-5. Cancer Treat Rev. 1979. PMID: 394834 Review. No abstract available.
-
The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review.Recent Results Cancer Res. 1980;74:98-106. doi: 10.1007/978-3-642-81488-4_14. Recent Results Cancer Res. 1980. PMID: 7003663 Review.
-
Podophyllotoxin derivatives VP-16 and VM-26.Cancer Chemother Biol Response Modif. 1988;10:57-63. Cancer Chemother Biol Response Modif. 1988. PMID: 3079398 Review. No abstract available.
-
Podophyllotoxin derivatives VP-16 and VM-26.Cancer Chemother Biol Response Modif. 1987;9:67-70. Cancer Chemother Biol Response Modif. 1987. PMID: 3079416 Review. No abstract available.
Cited by
-
Podophyllotoxin derivative VP 16-213.Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976. Cancer Chemother Pharmacol. 1979. PMID: 389478 Review.
-
[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].Klin Wochenschr. 1981 Nov 2;59(21):1177-88. doi: 10.1007/BF01721212. Klin Wochenschr. 1981. PMID: 7031350 Clinical Trial. German.
-
The clinical pharmacology of VM26 and VP16-213. A brief overview.Cancer Chemother Pharmacol. 1982;7(2-3):133-40. doi: 10.1007/BF00254535. Cancer Chemother Pharmacol. 1982. PMID: 7044592 Review. No abstract available.
-
The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation.Cancer Chemother Pharmacol. 1989;24(5):329-31. doi: 10.1007/BF00304768. Cancer Chemother Pharmacol. 1989. PMID: 2758563
-
Schedule-dependent topoisomerase II-inhibiting drugs.Cancer Chemother Pharmacol. 1994;34 Suppl:S84-8. doi: 10.1007/BF00684869. Cancer Chemother Pharmacol. 1994. PMID: 8070033 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources